Immunotherapy combination shows significant benefit for patients with advanced melanoma
A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. The trial, known as the RELATIVITY-047 study was co-led by Dana-Farber Cancer...
Learn more >
FDA approval offers hope for prevention of acute graft-versus-host disease
Approval of the drug abatacept opens up bone marrow transplant as an option for many more patients with cancer or blood disorders — especially patients of diverse ethnicities, who have extra difficulty finding a good match
The U.S. Food and Drug Administration (FDA) today approved a treatment...
Learn more >
Targeted drug combination shows unprecedented activity in some highly aggressive brain tumors
Treatment with dabrafenib and trametinib yielded encouraging rate of durable responses in both high-grade and low-grade brain tumors carrying the rare BRAF v600E mutation
Study is first to show benefit of any targeted drugs in glioblastomas – the most aggressive brain tumor
Routine testing for BRAF...
Learn more >
Venetoclax shown to benefit patients with Waldenström Macroglobulinemia, including some who relapsed after previous therapy
Drug represents a highly effective and safe oral based treatment approach for Waldenström macroglobulinemia, study leaders say.
A drug that strips cancer cells of their quest for immortality represents an effective new option for patients with Waldenström macroglobulinemia, including those not...
Learn more >
Dana-Farber research supports FDA approval of immunotherapy drug given after surgery for certain patients with kidney cancer
Pembrolizumab is the first drug approved as adjuvant therapy for patients with kidney cancer considered at high risk of relapse
An immunotherapy drug given as a treatment following kidney cancer surgery, whose clinical testing was led by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, becomes...
Learn more >
First FDA approval of CAR T-cell therapy for multiple myeloma marks milestone for patients
Approval of ide-cel for adults who have relapsed after four or more prior lines of therapy follows clinical trials led by Dana-Farber Cancer Institute investigators
The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma,...
Learn more >